An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
Abemaciclib and paclitaxel showed moderate clinical benefits for CDK4/6-activated tumors. We identified a poor genetic group characterized by bypass signaling pathway activation and/or CCNE amplification, which negatively affected treatment response and survival. Future studies with homogeneous patient groups are required to validate these findings.
Authors
- H.R. Kim
- Kyoo Hyun Kim (ORCID: https://orcid.org/0000-0002-7871-2142)
- Sun Young Rha (ORCID: https://orcid.org/0000-0002-2512-4531)
- C.G. Kim
- Minsun Jung (ORCID: https://orcid.org/0000-0002-8701-4282)
- M.H. Kim
- Seung‐Hoon Beom (ORCID: https://orcid.org/0000-0001-7036-3753)
- Changhee Park (ORCID: https://orcid.org/0000-0002-7125-9795)
- Hyo Song Kim (ORCID: https://orcid.org/0000-0002-0625-9828)
- Su‐Jin Shin (ORCID: https://orcid.org/0000-0001-9114-8438)
Institutions
- Yonsei University (KR)
- Seoul National University Hospital (KR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104106
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Eli Lilly and Company
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea